

DAFTAR PUSTAKA

- Adiputra, I., Trisnadewi, N., Oktaviani, N. P., Munthe, S. A., Hulu, V., Faridi, A., & Fitriani, R. 2021. *Metodologi Penelitian Kesehatan*. Yayasan Kita Menulis, Jakarta.
- Amoghmath, S., & Majagi, S. 2017. Drug Induced Kidney Disease. *Open Access Journal of Toxicology*. 2(1): 1–3.
- Ayaz, C., Celen, M., Dal, T., Deveci, O., Bayan, K., Mert, D., *et al.* 2015. Tenofovir disoproxil fumarate treatment in HbeAg-positive patients. *Le Infezioni In Medicina*. 33(1): 31–35.
- Bastiangga, D., Hapsari, R. 2019. Profil Imunitas terhadap Virus Hepatitis B pada Tenaga Kesehatan di Rumah Sakit Nasional Diponegoro Semarang. *Jurnal Kedokteran Diponegoro*. 8(4): 1338–1350.
- Bierhoff, M., Smolders, E. J., Taming, J., Burger, D. M., Spijker, R., Rijken, M. J., *et al.* 2019. Pharmacokinetics of oral tenofovir disoproxil fumarate in pregnancy and lactation: A systematic review. *International Medical Press*. 24(7): 529–540.
- Brookes, E. M., Power, D. A. 2022. Elevated Serum Urea-to-Creatinine Ratio is Associated with Adverse Inpatient Clinical Outcomes in Non-end stage Chronic Kidney Disease. *Scientific Reports Journal*. 12(1): 1–10.
- Buti, M., Gane, E., Seto, W. K., Chan, H. L. Y., Chuang, W. L., Stepanova, T., *et al.* 2016. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for the Treatment of Patients with HBeAg-negative Chronic Hepatitis B Virus Infection: a Randomised, Double-blind, Phase 3, non-inferiority trial. *The Lancet Gastroenterology and Hepatology*. 1(3): 196–206.
- Chen, M. bing, Wang, H., Zheng, Q. han, Zheng, X. wen, Fan, J. nuo, Ding, Y. long, & Niu, J. li. 2019. Comparative Efficacy of Tenofovir and Entecavir in Nucleos(t)ide Analogue-naïve Chronic Hepatitis B: A Systematic Review and Meta-Analysis. *Public Library of Science Journal*, 14(11): 1–13.
- Chuang, Y. C., Tsai, K. N., Ou, J. H. J. 2022. Pathogenicity and Virulence of Hepatitis B virus. *Virulence*. 13(1): 258–296.
- Costanzo, L. S. 2014. *Physiology 5th Edition*. Elsevier, Philadelphia.
- Dinas Kesehatan Jawa Tengah. 2023. *Profil Kesehatan Jawa Tengah Tahun 2023*. Dinkes Jateng, Semarang.
- Dobrek, L. 2023. A Synopsis of Current Theories on Drug-Induced Nephrotoxicity. *Life Journal*. 13(2), 1–22.
- Dodiet, A. S. 2021. *Hipotesis dan Variabel Penelitian*. Tahta Media, Jakarta.

- Fioroti, C. E., Distenhreft, J. I., Paulino, B. B., Lacchine, K., Ramos, D. R., Seguro, A. C., Luchi, W. M. 2022. Tenofovir-induced Renal and Bone Toxicity: Report of Two Cases and Literature Review. *Revista Do Instituto de Medicina Tropical de Sao Paulo*. 64(1): 1–7.
- Fortuna, F., Yuniarti, E. 2021. Pengaruh Latihan Beban Terhadap Kadar Kreatinin pada Anggota Pusat Kebugaran Universitas Negeri Padang. *Prosiding Seminar Nasional Biologi*. 2(1): 1686–1692.
- Fujii, T., Kawasoe, K., Ohta, A., Nitta, K. 2019. A Case of Entecavir-Induced Fanconi Syndrome. *Japanese Society of Nephrology*. 8(4): 256–260.
- Gorelik, Y., Abassi, Z., Bloch-Isenberg, N., Khamaisi, M., Heyman, S. N. 2022. Changing Serum Creatinine in the Detection of Acute Renal Failure and Recovery Following Radiocontrast Studies among Acutely Ill Inpatients: Reviewing Insights Regarding Renal Functional Reserve Gained by Large-Data Analysis. *Practical Laboratory Medicine*. 30: 1–6.
- Han, E., Kim, S., Lee, H., Jeon, S., Jung, Y., Yim, H. 2010. Entecavir-induced Tubulointerstitial Nephritis. *Korean Journal of Nephrology*. 29(4): 504–508.
- Heriansyah, Humaedi, A., Widada. 2019. Gambaran Ureum dan Kreatinin pada Pasien Gagal Ginjal Kronis di RSUD Karawang. *Binawan Student Journal*. 1(1): 8–14.
- Hustrini, N. M. 2019. Tenofovir dan Gangguan Fungsi Ginjal pada HIV. *Jurnal Penyakit Dalam Indonesia*. 6(3): 106–108.
- Iannacone, M., Guidotti, L. G. 2022. Immunobiology and Pathogenesis of Hepatitis B Virus Infection. *Nature Reviews Immunology*. 22(1): 19–32.
- Jafari, A., Khalili, H., Dashti-Khavidaki, S. 2014. Tenofovir-induced Nephrotoxicity: Incidence, Mechanism, Risk Factors, Prognosis and Proposed Agents for Prevention. *European Journal of Clinical Pharmacology*. 70(9): 1029–1040.
- Jin, Y., Wang, S., Xu, S., Zhao, S., Xu, X., Poongavanam, V., *et al.* 2023. Targeting Hepatitis B Virus cccDNA Levels: Recent Progress in Seeking Small Molecule Drug Candidates. *Drug Discovery Today*. 28(7): 1–16.
- Jung, W. J., Jang, J. Y., Park, W. Y., Jeong, S. W., Lee, H. J., Park, S. J., *et al.* 2018. Effect of Tenofovir on Renal Function in Patients with Chronic Hepatitis B. *Medicine Journal*. 97(7): 1–7.
- Katzung, B.G., Masters, S.B. & Trevor, A.J. 2016. *Farmakologi Dasar & Klinik*. Edisi 12. EGC, Jakarta.
- Karayiannis, P. 2017. Hepatitis B Virus: Virology, Molecular Biology, Life Cycle and Intrahepatic Spread. *Hepatology Internasional*. 11(6): 500–508.

- Kawuma, A. N., Wasmann, R. E., Sinxadi, P., Sokhela, S. M., Chandiwana, N., Venter, W. D. F., *et al.* 2023. Population Pharmacokinetics of Tenofovir Given as Either Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide in an African Population. *Pharmacometrics and Systems Pharmacology*. 12(6), 821–830.
- Kearney, B. P., Flaherty, J. F., & Shah, J. 2004. Tenofovir Disoproxil Fumarate Clinical Pharmacology and Pharmacokinetics. *Clinical Pharmacokinetics Journal*. 43(9): 595–612.
- Kementerian Kesehatan. 2017. *Riset Kesehatan Dasar*. Badan Penelitian Dan Pengembangan Kesehatan, Jakarta.
- Kementrian Kesehatan. 2019. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Hepatitis B. Kementrian Kesehatan, Jakarta.
- Lourenço, T., Vale, N. 2023. Entecavir: A Review and Considerations for Its Application in Oncology. *Pharmaceuticals*. 16(11): 1–12.
- Lutvyani, A., Tjempakasari, A., Rejeki, P. 2021. Long-Term Ketogenic Diet alters Kidney Function through Increasing Serum Creatinine Levels in Mice. *Journal of Hunan University*. 48(2): 113–120.
- Madihi, S., Madihi, S., Syed, H., Lazar, F., Ziad, A., Benani, A. 2020. A Systematic Review of the Current Hepatitis B Viral Infection and Hepatocellular Carcinoma Situation in Mediterranean Countries. *Biomedical Research Internasional*. 20(20): 1–16.
- Malfica, M. J., Rosita, L., & Yuantari, R. 2023. Hubungan Ureum dan Kreatinin Serum dengan Lamanya Terapi Hemodialisis pada Pasien Penyakit Ginjal Kronis (PGK) di RS PKU Bantul. *Berkala Ilmiah Kedokteran dan Kesehatan Masyarakat*. 1(1) : 1-18.
- Mandíková, J., Volková, M., Pávek, P., Navrátilová, L., Hyršová, L., Janeba, Z., *et al.* 2016. Entecavir Interacts with Influx Transporters hOAT1, hCNT2, hCNT3, but not with hOCT2: The Potential for Renal Transporter-mediated Cytotoxicity and Drug-drug Interactions. *Frontiers in Pharmacology*. 6(1): 1–11.
- Mardhatillah, H., Sukmawati, N., Gayatri, A. 2019. Prevalensi dan Karakteristik Gangguan Fungsi Ginjal pada Pasien HIV yang Menggunakan Terapi ERV Berbasis Tenofovir di RSUP Sanglah Denpasar. *Jurnal Medika Udayana*. 8(11): 1–9.
- Mehta, P., Kumar, R. P. 2022. *Hepatitis*. Statpearls Publishing, Treasure Island.
- Ning, L., Lin, W., Hu, X., Fan, R., Liang, X., Wu, Y., *et al.* 2017. Prevalence of Chronic Kidney Disease in Patients with Chronic Hepatitis B: A Cross-Sectional Survey. *Journal of Viral Hepatitis*. 24(11): 1043–1051.

- Nurhayati, Safira, R., Dani, H., Fandiata, Handayani. 2021. Profile of Urea and Creatinine Levels and the Characteristic Factors of Hypertensive Patients at Bhayangkara Hospital Palembang. *Journal of Medical Laboratory and Science*. 1(2): 21–31.
- Odenwald, M. A., Paul, S. 2022. Viral hepatitis: Past, Present, and Future. *World Journal of Gastroenterology*. 28(14): 1405–1429.
- Paulsen F, & Waschke J. *Sobotta Atlas Anatomi Manusia: Organ-Organ*. Dalam. Edisi 23. EGC, Jakarta.
- Perazella, M. A., Rosner, M. H. 2022. Drug-Induced Acute Kidney Injury. *Clinical Journal of the American Society of Nephrology*. 17(8): 1220–1233.
- Perri, G. 2021. Tenofovir Alafenamide (TAF) Clinical Pharmacology. *Le Infezioni in Medicina*. 29(4): 526–529.
- Rachmad, B., Setyawati, R. 2023. Gambaran Kadar Kreatinin dan Ureum pada Penderita Diabetes Mellitus. *Jurnal Medical Laboratoty*. 2(2): 37–45.
- Richfield, O., Cortez, R., Navar, L. G. 2024. Modeling the Interaction between Tubuloglomerular Feedback and Myogenic Mechanisms in the Control of Glomerular Mechanics. *Frontiers in Physiology*. 15(1): 1–16.
- Ray, A. S., Cihlar, T., Robison, K. L., Tong, L., Vella, J. E., Fuller, M. D. *et al*. 2006. Mechanism of Active Renal Tubular Efflux of Tenofovir. *Antimicrobial Agents And Chemotherapy*. 50(10): 3297-3304.
- Sabeena, S., Ravishankar, N. 2022. Horizontal Modes of Transmission of Hepatitis B Virus (HBV): A Systematic Review and Meta-Analysis. *Iran Journal Public Health*. 51(10): 2181–2193.
- Sales, G. T. M., Foresto, R. D. 2020. Drug-induced Nephrotoxicity. *Revista Da Associacao Medica Brasileira*. 66(1): 82–90.
- Shi, H., Huang, M., Lin, G., Li, X., Wu, Y., Jie, Y. 2016. Efficacy Comparison of Tenofovir and Entecavir in HBeAg-positive Chronic Hepatitis B Patients with High HBV DNA. *Biomedical Research Internasional*. (6725073): 1–6.
- Sherwood, L. 2016. *Fisiologi Manusia Dari Sel ke Sistem*. Edisi 8. EGC, Jakarta.
- Soriano, R. M., Penfold, D., Leslie, S. 2023. *Anatomy, Abdomen and Pelvis, Pelvis*. Statpearls Publisher, Treasure Island.
- Tjokroprawiro, A., Setiawan, P., Santoso, D., Soegiarto, G., Rahmawati, L. 2015. *Buku Ajar Ilmu Penyakit Dalam Universitas Airlangga*. Airlangga Univesity Press, Surabaya.
- Trinh, S., Le, A. K., Chang, E. T., Hoang, J., Jeong, D., Chung, M. 2019. Changes in Renal Function in Patients With Chronic HBV Infection Treated With

- Tenofovir Disoproxil Fumarate vs Entecavir. *Clinical Gastroenterology and Hepatology*. 17(5): 948–956.
- Tripathi, N., Omar, Y., Mousa. 2023. *Hepatitis B*. StatPearls Publishing, Treasure Island.
- Tsukuda, S., Watashi, K. 2020. Hepatitis B virus biology and life cycle. *Antiviral Research*. 18(2): 1–10.
- Venter, W. D. F., Fabian, J., Feldman, C. 2018. An overview of Tenofovir and Renal Disease for the HIV-treating Clinician. *Southern African Journal of HIV Medicine*. 19(1): 1–8.
- Villa, D., Navas, M. C. 2023. Vertical Transmission of Hepatitis B Virus—An Update. *Microorganisms Journal*. 11(5): 1–20.
- Wang, G., & Duan, Z. 2021. Guidelines for Prevention and Treatment of Chronic Hepatitis B. *Journal of Clinical and Translational Hepatology*. 9(5): 769–791.
- Wassner, C., Bradley, N., Lee, Y. 2020. A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide. *Journal of the International Association of Providers of AIDS Care*. 19(1): 1–10.
- World Health Organization. 2017. *Guidelines on Hepatitis B and C Testing*. World Health Organization, Jenewa.
- World Health Organization. 2021. *Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021*. World Health Organization, Jenewa.
- Wu, X., Cai, S., Li, Z., Zheng, C., Xue, X., Zeng, J., & Peng, J. 2016. Potential Effects of Telbivudine and Entecavir on Renal Function: A Systematic Review and Meta-analysis. *Virology Journal*. 13(1): 1–9.
- Yang, Y. M., Choi, E. J. 2017. Renal Safety of Tenofovir and/or Entecavir in Patients with Chronic HBV Monoinfection. *Dove Medical Press*. 13(1): 1273–1285.
- Yazie, T. S., Orjino, T. A., Degu, W. A. 2019. Reduced Kidney Function in Tenofovir Disoproxil Fumarate Based Regimen and Associated Factors: A Hospital Based Prospective Observational Study in Ethiopian Patients. *International Journal of Nephrology*. (9172607): 1–9.
- You, H., Wang, F., Li, T., Xu, X., Sun, Y. 2023. Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022). *Journal of Clinical and Translational Hepatology*. 11(6): 1425–1442.
- Yulia, D. 2019. Virus Hepatitis B Ditinjau dari Aspek Laboratorium. *Jurnal Kesehatan Andalas*. 8(4): 247–254.